Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | ITGAL | P20701 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.34 |
| ▸ | TMPRSS15 | P98073 | 2/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23366203 | 0.93 | ENPEP (0.40) | ECE1ENPEPPTPN1PRSS1TMPRSS15 | |
| SCHEMBL23366240 | 0.93 | ENPEP (0.40) | ECE1ENPEPPTPN1PRSS1TMPRSS15 | |
| SCHEMBL23366206 | 0.93 | ENPEP (0.40) | ECE1ENPEPPTPN1PRSS1TMPRSS15 | |
| SCHEMBL1246595 | 0.81 | ECE1 (0.53) | ECE1CA2CA1MEN1KMT2A | |
| SCHEMBL7258586 | 0.81 | ECE1 (0.53) | ECE1CA2CA1MEN1KMT2A | |
| SCHEMBL150536 | 0.81 | ECE1 (0.53) | ECE1CA2CA1MEN1KMT2A | |
| SCHEMBL6852847 | 0.81 | ECE1 (0.53) | ECE1CA2CA1MEN1KMT2A | |
| SCHEMBL6136566 | 0.81 | ECE1 (0.53) | ECE1CA2CA1MEN1KMT2A | |
| SCHEMBL7148009 | 0.81 | ECE1 (0.53) | ECE1CA2CA1MEN1KMT2A | |
| SCHEMBL31182997 | 0.81 | ECE1 (0.53) | ECE1CA2CA1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11007274-B2 | Compounds for medicinal applications | AusVir Therapeutics Pty Ltd (AU) | 2021-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11007274-B2 | Compounds for medicinal applications | HAVCR2, ENGASE, DNPEP | ECE1 594/4885CA2 246/4885CA1 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.